BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024

Rhea-AI Summary

BioRestorative Therapies (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, has announced it will release its second quarter 2024 financial results after market close on Tuesday, August 13, 2024. Following the announcement, the company's management will host a conference call to review the financial results and provide a business update.

The conference call details are as follows:

• Date: Tuesday, August 13, 2024
• Time: 4:30 p.m. ET
• Domestic: 1-877-545-0523
• International: 1-973-528-0016
• Access Code: 151026

The call will also be broadcast live and archived on the company's website at https://www.biorestorative.com/investor-relations/ under "Events."

MELVILLE, N.Y., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it will release its second quarter 2024 financial results after market close on Tuesday, August 13, 2024. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update.

Second Quarter 2024 Results Conference Call Details:

Date:	Tuesday, August 13, 2024
Time:	4:30 p.m. ET
Domestic:	1-877-545-0523
International:	1-973-528-0016
Access Code:	151026

The call will also be broadcast live and archived on the Company's website at https://www.biorestorative.com/investor-relations/ under “Events.”

About BioRestorative Therapies, Inc.

BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we have also recently begun offering BioCosmeceutical products:

• Disc/Spine Program (brtxDISC^™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

• Metabolic Program (ThermoStem^®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.

• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via Investigational New Drug (IND)-enabling studies, with the aim of pioneering U.S. Food and Drug Administration (FDA) approvals in the emerging BioCosmeceuticals space.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:

Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com

FAQ

When will BioRestorative Therapies (BRTX) release its Q2 2024 financial results?

BioRestorative Therapies (BRTX) will release its second quarter 2024 financial results after market close on Tuesday, August 13, 2024.

What time is the BioRestorative Therapies (BRTX) Q2 2024 earnings call?

The BioRestorative Therapies (BRTX) Q2 2024 earnings call is scheduled for 4:30 p.m. ET on Tuesday, August 13, 2024.

How can I access BioRestorative Therapies' (BRTX) Q2 2024 earnings call?

You can access BioRestorative Therapies' (BRTX) Q2 2024 earnings call by dialing 1-877-545-0523 (domestic) or 1-973-528-0016 (international) and using the access code 151026. The call will also be broadcast live on the company's website.

Where can I find the archived version of BioRestorative Therapies' (BRTX) Q2 2024 earnings call?

The archived version of BioRestorative Therapies' (BRTX) Q2 2024 earnings call will be available on the company's website at https://www.biorestorative.com/investor-relations/ under the 'Events' section.